something positive? part 1: there isn't much positive to say about cytodyn (below though - i gave it my all on the positives). the positives are also buried by the astounding negatives. but, i'll indulge you. i have stated positive things many times. i do however post 999 times negatively for each 1 time positively. but here goes... as far as LERONLIMAB... NOT CYTODYN... not yet... and keep in mind you own stock in CYTODYN. you do not own stock in leronlimab...
i personally think the drug works and imo its very safe. i personally would request the drug if i were in bad shape with covid and it were available. imo its good enough for approval in various HIV indications. not sure on covid even though i'd try it. might also be good enough in other indications. it could be a very versatile important drug 20 years from now. or... it might be good at a lot of things but not great at more than 1 or 2. it may prove to be fascinating but completely unnecessary. even in HIV... its not needed. not until they work out the functional cure preclinical data. for MDR HIV lenacapivir is superior.
as far as CYTODYN? there are very few positives i can even spin never mind believe in. the former teams - nader's team and the predecessors were hands down atrocious. as far as the current team, well, there isn't a team. you have 3 execs (i didn't count the CFO) and a stats guy. the stats guy has nothing to do. cunningham and meidling have expertise mainly in project management and materials / supply chain; not the greatest fit for the current needs at cytodyn. i really don't think they have much to contribute, despite being bright people with deep pharma industry experience. they have no therapeutic development or regulatory filing experience at all. and they spent decades managing others, not DOING the work.
